In a patient with chronic kidney disease not on dialysis, when is statin therapy indicated for primary or secondary cardiovascular prevention, how should the dose be adjusted for an estimated glomerular filtration rate below 30 mL/min, and should statins be initiated or continued in patients receiving chronic dialysis?

Statin Therapy in Chronic Kidney Disease

In patients with CKD not on dialysis (eGFR <60 mL/min/1.73 m²), initiate moderate-intensity statin therapy for cardiovascular prevention; continue statins if already prescribed when dialysis begins, but do not start statins in dialysis-dependent patients.

CKD Not on Dialysis (eGFR <60 mL/min/1.73 m²)

When to Initiate Statins

Start statin therapy in all adults aged 40-75 years with CKD (eGFR <60 mL/min/1.73 m²) who have LDL-C 70-189 mg/dL and 10-year ASCVD risk ≥7.5%. CKD itself is a risk-enhancing factor that elevates cardiovascular risk to levels comparable to diabetes mellitus 1. The presence of albuminuria (albumin-to-creatinine ratio ≥30 mcg/mg) further multiplies this risk 1.

The evidence is robust: statins reduce major cardiovascular events by approximately 28% (RR 0.72), all-cause mortality by 17% (RR 0.83), cardiovascular death by 23% (RR 0.77), and myocardial infarction by 45% (RR 0.55) in CKD patients not requiring dialysis 2. The SHARP trial demonstrated these benefits extend across all eGFR categories from G3a to G5 3.

Dosing Recommendations

Use moderate-intensity statin therapy (equivalent to simvastatin 20-40 mg daily or atorvastatin 10-20 mg daily) or moderate-intensity statin combined with ezetimibe 1. The benefit is consistent across eGFR stages, though the relative risk reduction per unit LDL-C lowering may be slightly lower with more advanced CKD 1.

No routine dose adjustment is required for eGFR <30 mL/min/1.73 m² in non-dialysis patients. The guidelines do not specify different dosing based on eGFR thresholds; rather, they recommend moderate-intensity therapy across all CKD stages not requiring dialysis 3, 1.

Primary vs. Secondary Prevention

Statins provide benefit for both primary and secondary prevention in CKD, though the absolute benefit is greater in secondary prevention due to higher baseline risk 3. Recent evidence confirms statins reduce death and major cardiovascular events by about 20% even in primary prevention populations with CKD 2, 4.

Dialysis-Dependent CKD

Do Not Initiate Statins

In adults requiring chronic dialysis who are not currently on statin therapy, do not start a statin 1. This is a Class III (No Benefit) recommendation based on high-quality evidence from multiple large RCTs that failed to demonstrate benefit in prevalent dialysis patients 3, 1.

Three major trials in dialysis populations showed no conclusive cardiovascular benefit, suggesting that even if statins prevent some events, the magnitude of benefit is substantially smaller than in earlier CKD stages 3. The proportion of deaths attributable to atherosclerotic events is lower in dialysis patients, raising the issue of competing risks 1.

Continue Statins if Already Prescribed

If a patient is already taking a statin when dialysis begins, continue the medication 3, 1. This is a reasonable approach (Class IIb recommendation) based on the SHARP trial, where over 30% of participants transitioned to dialysis during follow-up and continued to show benefit 3, 1.

The rationale: patients who transition to dialysis may be systematically different from prevalent dialysis patients, and discontinuing effective therapy at dialysis initiation lacks supporting evidence 3. However, recent observational data from Korea suggests continuing statins in dialysis patients is associated with reduced cardiovascular events and mortality (adjusted HR 0.51), with benefits observed even in statin-naïve patients who initiate therapy on dialysis 5. This conflicts with guideline recommendations but represents emerging real-world evidence.

Clinical Approach for Dialysis Patients

For patients already on statins at dialysis initiation:

• Continue the current statin regimen without automatic discontinuation
• Periodically review the clinical status and revisit the decision as the patient's condition evolves 3
• Consider patient preferences regarding uncertain and potentially small cardiovascular benefits 3

For statin-naïve dialysis patients:

• Do not routinely initiate based on current guideline recommendations 1
• Consider initiation only in highly selected cases (e.g., very high LDL-C, strong patient preference after informed discussion) 3
• Be aware that emerging observational data suggests potential benefit, though this conflicts with RCT evidence 5

Important Caveats

Avoid fibrates in combination with statins in CKD patients due to increased toxicity risk 6. Ezetimibe monotherapy is not recommended; use it only in combination with statins 6.

Monitor for adverse effects, though systematic reporting in trials has been limited. Statins appear to have little effect on elevated liver enzymes or withdrawal due to adverse events in CKD populations 2. However, the risk of rhabdomyolysis and elevated creatinine kinase remains unclear due to insufficient reporting 2.

The decision differs fundamentally based on dialysis status: CKD not on dialysis represents a high-benefit population where statins should be standard therapy, while dialysis-dependent CKD represents a population where initiation shows no proven benefit in RCTs, though continuation of existing therapy is reasonable 3, 1.